A prominent example is uncovering the resistance mechanism of trastuzumab – a recombinant humanized monoclonal antibody that binds with the human epidermal growth factor receptor protein (HER2) in HER2+ breast cancer (BC) patients. The gene discussed is ERBB2; the disease is breast cancer.